First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 667 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology MOST POPULAR FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or... May 9, 2025 Sun Safety May 20, 2022 Breast Cancer Survivor Opens Her Own Business 17 Years After Beating... February 25, 2021 ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ March 8, 2019 Load more HOT NEWS Cancer in My Community: Addressing Regional Cancer Disparities in Peru Women Who Consume Cows’ Milk Increase Their Risk Of Breast Cancer... Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma Therapy Rottweiler, known as Dogtor Loki, Is Delivering ‘Hero Healing Kits’...
